Merck Presents on Phase 2b for HIV-1 Therapy Islatravir at IAS 2019

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the results from a Phase 2b clinical trial evaluating the efficacy, tolerability, and safety of islatravir (MK-8591), the company’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), for the treatment of HIV-1.

The trial evaluated three oral, once-daily doses of islatravir initially for 24 weeks in combination with Merck’s doravirine (a non-nucleoside reverse transcriptase inhibitor [NNRTI]) plus lamivudine (3TC, 300 mg), and then for a further 24 weeks in combination with doravirine, compared to DELSTRIGO (doravirine 100 mg/3TC 300 mg/tenofovir disoproxil fumarate 300 mg) in adults with HIV-1 infection who had not previously received antiretroviral treatment. At all dose levels, the combination of islatravir and doravirine maintained antiviral activity as measured by the number of study participants achieving HIV-1 RNA levels.

https://www.marketscreener.com/MERCK-AND-COMPANY-13611/news/Merck-and-Announces-Presentation-of-Phase-2b-Results-for-Investigational-HIV-1-Therapy-Islatravir-28957115/